Helen of Troy expands portfolio
This article was originally published in The Rose Sheet
Executive Summary
Company will introduce personal care products under the Toni & Guy and Bed Head by Tigi brand names in North and South America early next year, under a licensing agreement with Stone America announced Dec. 11. A marketing campaign will roll out to the U.S. before expanding to other markets next year; product shipments are slated to begin in 2007. "We are excited about the prospects for these brands and hope that products sold under these trademarks will become one of the most significant personal care categories for Helen of Troy over the long term," President and CEO Gerald Rubin stated. The firm's portfolio includes Revlon, Sea Breeze and Vidal Sassoon...
You may also be interested in...
Helen of Troy Q4 and 2007
Revenue grew 7% to $143.8 mil. during the fourth quarter (ended Feb. 28) on sales of personal-care appliances in Europe and the U.S., firm reports May 11. The quarter marked the completion of the product development process for the new Bed Head by TIGI line, expected to launch during Q2, CEO Gerald J. Rubin says. The company announced last year that it would unveil products under the Bed Head and Toni & Guy brands (1"The Rose Sheet" Dec. 18, 2006, In Brief). 2007 sales grew 7.7% to $634.9 mil. on increases in all areas of business, firm says. In 2008, Helen of Troy will focus on domestic placement of Bed Head and on international sales of Toni & Guy, with sales expected to top $660 mil. The recent acquisition of Belson Products also will provide "additional growth opportunity" for the professional appliance division, Rubin adds (2"The Rose Sheet" May 14, 2007, In Brief)...
Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Gel
Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.
US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says
The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.